2023-04-27 09:47:28 ET
- Evaxion Biotech ADS press release ( EVAX ): Q4 GAAP EPS of -$0.98.
- As of December 31, 2022, cash and cash equivalents were $13.2 million as compared to $32.2 million as of December 31, 2021.
- Research and Development expenses were $17.1 million for the year ended December 31, 2022 as compared to $19.6 million for the year ended December 31, 2021.
- General and Administrative expenses were $8.2 million for the year ended December 31, 2022 compared to $6.3 million for the year ended December 31, 2021.
For further details see:
Evaxion Biotech ADS GAAP EPS of -$0.98